{"title":"Teratogenic effects of bilirubin--a study using chick embryotoxicity screening test (CHEST).","authors":"M Peterka, I Miler, R Jelínek","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Using the Chick Embrotoxicity Screening Test (CHEST), two samples of bilirubin of different commercial origin were tested on 2, 3 and 4- day old chick embryos. Water soluble Bilirubin Lachema (containing 20 mg albumin per 1 ml) had no teratogenic effect. On the opposite, Bilirubin Merck (containing 8 mg albumin per 1 ml) manifested an apparent teratogenic potential when single doses 0.2 and 0.6 micrograms were administered intraamniotically on day 4. Dose-dependent malformations of brain and eyes, cleft beak and reduction deformities of limbs were observed. No such effects could be produced by administration of Bilirubin Merck on either day 2 and 3. A tentative explanation of the difference between teratogenic properties of Merck and Lachema bilirubin preparations may be sougth in the different proportion of the free and albumin bound fractions.</p>","PeriodicalId":12562,"journal":{"name":"Functional and developmental morphology","volume":"4 1","pages":"29-32"},"PeriodicalIF":0.0000,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Functional and developmental morphology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Using the Chick Embrotoxicity Screening Test (CHEST), two samples of bilirubin of different commercial origin were tested on 2, 3 and 4- day old chick embryos. Water soluble Bilirubin Lachema (containing 20 mg albumin per 1 ml) had no teratogenic effect. On the opposite, Bilirubin Merck (containing 8 mg albumin per 1 ml) manifested an apparent teratogenic potential when single doses 0.2 and 0.6 micrograms were administered intraamniotically on day 4. Dose-dependent malformations of brain and eyes, cleft beak and reduction deformities of limbs were observed. No such effects could be produced by administration of Bilirubin Merck on either day 2 and 3. A tentative explanation of the difference between teratogenic properties of Merck and Lachema bilirubin preparations may be sougth in the different proportion of the free and albumin bound fractions.